Premium
Onycholysis as a complication of systemic chemotherapy
Author(s) -
Hussain Sabir,
Anderson Di.,
Salvatti Mary Ellen,
Adamson Barbara,
McManus Margaret,
Braverman Albert S.
Publication year - 2000
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(20000515)88:10<2367::aid-cncr22>3.0.co;2-#
Subject(s) - onycholysis , medicine , complication , dermatology , chemotherapy , surgery
BACKGROUND Onycholysis has been reported in association with the use of several noncytotoxic drugs and with chemotherapy in 135 patients. Onycholysis may be precipitated by exposure to ultraviolet radiation. METHODS The authors studied 91 patients who received paclitaxel and 187 patients who received doxorubicin. RESULTS Onycholysis occurred in 5 of 21 patients who received > 6 courses of weekly paclitaxel, developing in the summer months in all 5 patients. It did not occur in patients who received fewer weekly paclitaxel courses or those who were treated every 3 weeks. Onycholysis did not occur in 187 patients who received doxorubicin. Review of the literature revealed that onycholysis is nearly exclusively associated with anthracycline and taxane therapy. CONCLUSIONS Prolonged weekly paclitaxel, other taxanes, and anthracyclines cause onycholysis in some patients, which may be precipitated by exposure to sunlight. Patients receiving these drugs should protect their nails from sunlight. Cancer 2000;88:2367–71. © 2000 American Cancer Society.